-11.1%
CHRW vs GSK
+14.9%
-26.0%
-40.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | +5.0% | -4.8% | -0.7% |
| 7D | +4.9% | +4.9% | -0.1% | +3.9% |
| 30D | -4.8% | +9.9% | -14.7% | -5.9% |
| 3M | -13.1% | +0.2% | -13.3% | -13.3% |
| 6M | -16.3% | +2.3% | -18.7% | -16.7% |
| YTD | -15.8% | +7.1% | -22.9% | -16.7% |
| 1Y | -11.1% | +13.1% | -24.3% | -12.8% |
| All | -11.1% | +14.9% | -26.0% | -12.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling